Hofseth Biocare ASA HBC

Hofseth BioCare ASA ("HBC" or the "Company") today announces the appointment of Leif Arne Giske as new Chief Financial Officer (CFO) of the HBC Group, effective immediately. Mr. Giske has been with Hofseth BioCare since 2013 and previously held the position of Group Accounting Manager. Through this role he has had overall responsibility for the Group's accounting, financial reporting and control functions. Mr. Giske holds 3,339,384 shares in HBC and will be part of the Company's executive manage

HBC recorded total operating revenues of NOK 65.7 million in the second quarter of 2026, compared to NOK 68.4 million in the same period last year. Net operating revenues were NOK 63.1 million, down from NOK 67.8 million in Q2 2025. EBITDA for the quarter was negative NOK 2.7 million, compared to negative NOK 5.4 million in Q2 2025. The Operational EBITDA* amounted to negative NOK 0.6 million (positive NOK 1.3 million in Q2 2025), excluding non-recurring and strategic development costs such as c

Reference is made to the stock exchange announcements from Hofseth BioCare ASA ("HBC" or the "Company") published on 3 July 2026 regarding the private placement (the "Private Placement") of new ordinary shares ("Offer Shares") at a fixed price per share of NOK 1.30 (the "Offer Price"), which raised gross proceeds of approximately NOK 144.5 million. The Private Placement was divided into two tranches and the second tranche of 32,819,999 Offer Shares ("Tranche 2") was approved at the extraordinary

Hofseth BioCare ASA held an Extraordinary General Meeting on 30 July 2026. All proposals were resolved as presented in the notice issued on 9 July 2026. The minutes from the Extraordinary General Meeting are attached. For further information, please contact: Jon Olav Ødegård, CEO at HBC Phone: +47 936 32 966 E-mail: [email protected] About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resou

Reference is made to the stock exchange announcements by Hofseth BioCare ASA ("HBC" or the "Company") on 28 and 29 June 2026 regarding completion of delivery of Offer Shares in tranche 2 (the "T2 Offer Shares") where its subject to an extraordinary general meeting (the "EGM") resolving to inter alia, (i) issue the T2 Offer Shares in the Private Placement and (ii) amend the terms of the Company’s B-shares ("B-Shares Amendments"). The Board therefore calls for an EGM to be held at the offices of t

Hofseth BioCare ASA held its Annual General Meeting on 30 June 2026.All proposals were resolved as presented in the notice issued on 9 June 2026. The minutes from the Annual General Meeting are attached. For further information, please contact:Jon Olav Ødegård, CEO at HBCPhone: +47 936 32 966E-mail: [email protected] About Hofseth BioCare ASA:HBC is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full trac

Commercial update — second quarter 2026: Since the end of the first quarter, the Company has seen a very significant pick-up in commercial activity. Second-quarter top-line revenue is expected to be comparable to the second quarter of last year, a strong result given that production volumes in the second quarter are running approximately 40 % below the prior-year period. The improvement is evident across all of the Company's ingredients as tightness and demand in the market for marine proteins c

Reference is made to the stock exchange announcements from Hofseth BioCare ASA ("HBC" or the "Company") published on 26 June 2026 and 29 June 2026 regarding a private placement (the "Private Placement") of new ordinary shares ("Offer Shares") at a fixed price per share of NOK 1.30 (the "Offer Price"), which raised gross proceeds of approximately NOK 144.5 million. In the Private Placement, the following primary insiders or close associates of primary insiders were allocated Offer Shares in the P

Reference is made to the stock exchange announcements from Hofseth BioCare ASA ("HBC" or the "Company") published on 26 June 2026 and 29 June 2026 regarding a private placement (the "Private Placement") of new ordinary shares ("Offer Shares") at a fixed price per share of NOK 1.30 (the "Offer Price"), which raised gross proceeds of approximately NOK 144.5 million. The following shareholders of the Company have, on 28 June 2026, been allocated new shares in the Private Placement which implies tha

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Hofseth BioCare ASA ("HBC" or the "Company") today announces a contemplated private placement (the "Private Placement") of between 96,153,846 and 134,615,384 new shares ("Offer S

The Annual General Meeting of Hofseth BioCare ASA for 2026 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 30 June 2026 at 11:00 CEST. The notice of the Annual General Meeting is attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: +47 93632966 E-mail: [email protected] About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal ut